Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$113.25 USD

113.25
4,129,099

+0.16 (0.14%)

Updated Sep 27, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

by Kinjel Shah

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

Why Merck (MRK) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Strong Private Sector Payrolls in January

by Zacks Equity Research

Strong Private Sector Payrolls in January.

Mark Vickery headshot

ADP Posts Blowout +291K New Jobs for January

by Mark Vickery

Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

by Zacks Equity Research

Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

Should You Buy Merck (MRK) Ahead of Earnings?

by Zacks Equity Research

Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Merck's Recarbrio Gets FDA Priority Review for New Indication

by Zacks Equity Research

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.

Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn

by Zacks Equity Research

Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.

The Extreme Risks of Trading Your Own Retirement Assets - February 03, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative

by Kinjel Shah

Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.

Old Dominion (ODFL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Old Dominion's (ODFL) fourth-quarter 2019 results will likely reflect unfavorable impact of a soft freight environment.

Want To Retire Early? Learn the Intelligent Investing Secret - January 31, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Indrajit Bandyopadhyay headshot

Merck's Dificid Gets FDA Approval in Pediatric Indication

by Indrajit Bandyopadhyay

The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.

Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down

by Zacks Equity Research

Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.

The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $86.10, marking a +0.14% move from the previous day.

Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.